Optimi Health Launches Standardized Microdose Psilocybin Products for Clinical Research
Optimi Health completed production of 1mg and 2mg microdose psilocybin finished drug products specifically for clinical research organizations. The new dosage formats extend the company's psilocybin range, which currently includes a 5mg formulation prescribed in Australia for treatment-resistant depression.
Key figures
- Dosage 1
- 1mg
- Dosage 2
- 2mg
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.